BioCardia Inc (BCDA) FinancialsBCDABioCardia Inc

BioCardia Inc (BCDA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Reconstructive Division, accounting for 92.7% of total sales, equivalent to $521.00K. Another important revenue stream is Spine Division. Understanding this composition is critical for investors evaluating how BCDA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, BioCardia Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -1803.19%, provide a clear picture of how effectively BCDA converts its operational activities into shareholder value.

In the context of the broader market, BCDA competes directly with industry leaders such as GUTS and NCEL. With a market capitalization of $13.17M, it holds a significant position in the sector. When comparing efficiency, BCDA's gross margin of N/A stands against GUTS's N/A and NCEL's N/A. Such benchmarking helps identify whether BioCardia Inc is trading at a premium or discount relative to its financial performance.

BioCardia has reported consistent net losses, with a net income of -$2,259,000 in Q1 2026 and a gross margin of 0% in recent quarters. The company has not generated any gross profit since Q4 2024, indicating significant financial challenges.